

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



January 25, 2025

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-957-3090

(Update on Disclosed Matters)
Notice of Entry into Master Transaction Agreement with Roche Diagnostics K.K.

As announced in the "Notice concerning Memorandum of Understanding to enter into Master Transaction Agreement between TAUNS Laboratories, Inc. and Roche Diagnostics K.K." dated December 25, 2024, we hereby announce that we have entered into a Master Transaction Agreement with Roche Diagnostics K.K. (Nobu Ogasawara, President and CEO; hereinafter "Roche").

1. Details of the products to be sold by TAUNS to Roche

- (1) ImunoAce SARS-CoV-2 III (Sales Standard: 10 tests)
- (2) ImunoAce SARS-CoV-2/Flu (Sales Standard: 10 tests)

2. Sales launch

The start of sales of our company's products to Roche is scheduled for the last week of January 2025.

3. Outlook

At present, we believe that this alliance will have a minimal impact on the business performance of TAUNS, but we will disclose any significant impact as soon as it is identified.